Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VIT45 vs Oral Iron in NDD-CKD
NCT00317239Phase 3Completed
- Sponsor
- American Regent, Inc.
- Start
- May 2005
- Primary completion
- Feb 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ferric carboxymaltose in anemia (2 arms), sponsored by American Regent, Inc. Primary endpoint: Number of Subjects Achieving an Increase in Hemoglobin >=1g/dL. Started May 2005; status: completed.
02
Drugs
ferric carboxymaltose
03
Conditions
anemia
Beyond the preview
Go deeper on NCT00317239.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00317239.